Stocktoria
GRAIL, Inc. GRAL
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2024-06-12
GRAIL, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $147.2M | $125.6M | $93.1M |
| R&D expense | $195.8M | $322.4M | $338.7M |
| Operating income | -$562.2M | -$2.2B | -$1.5B |
| Income tax | -$126.2M | -$135.4M | -$42.0M |
| Net income | -$408.4M | -$2.0B | -$1.5B |
| EPS (diluted) | $-11.11 | $-63.54 | $-47.21 |
| Operating cash flow | -$299.0M | -$577.2M | -$595.8M |
| Free cash flow | -$299.9M | -$582.4M | -$608.7M |
| Cash & equivalents | $249.7M | $214.2M | $97.3M |
| Total assets | $2.9B | $3.0B | $3.9B |
| Total liabilities | $344.2M | $479.9M | $267.6M |
| Shareholders' equity | $2.6B | $2.5B | — |
Source: SEC EDGAR filings · CIK 0001699031 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.